Ly6/PLAUR Domain-Containing Protein 6: A Promising Drug Target and Biomarker

Target Name: LYPD6

NCBI ID: G130574

LYPD6

Ly6/PLAUR Domain-Containing Protein 6: A Promising Drug Target and Biomarker

Ly6/PLAUR domain-containing protein 6 (LYPD6) is a protein that is expressed in various tissues, including human tissues, and has been implicated in several biological processes. Ly6/PLAUR domain-containing protein 6 has also been identified as a potential drug target and biomarker. In this article, we will explore the biology of Ly6/PLAUR domain-containing protein 6, its potential as a drug target, and its potential as a biomarker for various diseases.

History of Ly6/PLAUR domain-containing protein 6

The study of Ly6/PLAUR domain-containing protein 6 (LYPD6) was first introduced in 2004 by Chen et al., who identified the protein as a new member of the PLAUR family, which is known for its role in cell adhesion and migration. Since then, several studies have further characterized the biology of Ly6/PLAUR domain-containing protein 6 (LYPD6).

Expression and localization of Ly6/PLAUR domain-containing protein 6

Ly6/PLAUR domain-containing protein 6 (LYPD6) is expressed in various tissues, including human tissues. Studies have shown that LYPD6 is expressed in various tissues, including brain, heart, liver, and pancreas. Additionally, the protein has been shown to be expressed in various cell types, including cancer cells, neurons, and immune cells.

Localization of LYPD6 has also been studied. Studies have shown that LYPD6 is predominantly localized to the cytoplasm of cells. Furthermore, the protein has been shown to be associated with the endoplasmic reticulum (ER) in some cell types.

Potential drug target

The potential drug target for LYPD6 is its unique structure and the various functions it is involved in. One potential mechanism by which LYPD6 could be a drug target is its role in cell adhesion and migration. As mentioned earlier, LYPD6 is a member of the PLAUR family and has been shown to play a role in cell adhesion and migration. Additionally, studies have shown that LYPD6 is involved in the regulation of cell survival.

Another potential mechanism by which LYPD6 could be a drug target is its role in cancer progression. As mentioned earlier, LYPD6 is involved in the regulation of cell survival and has been shown to be involved in the progression of several types of cancer.

Potential biomarker

LYPD6 has also been identified as a potential biomarker for several diseases. As mentioned earlier, studies have shown that LYPD6 is involved in the regulation of cell survival and has been shown to be involved in the progression of several types of cancer. Additionally, the protein has been shown to be involved in the regulation of inflammation.

Conclusion

In conclusion, LY6/PLAUR domain-containing protein 6 (LYPD6) is a protein that is expressed in various tissues and has been implicated in several biological processes. Additionally, the protein has been identified as a potential drug target and biomarker for several diseases. Further research is needed to fully understand the role of LYPD6 in biology and its potential as a drug target and biomarker.

Protein Name: LY6/PLAUR Domain Containing 6

Functions: Acts as a modulator of nicotinic acetylcholine receptors (nAChRs) function in the brain (PubMed:27344019, PubMed:34631692). Inhibits nicotine-induced Ca(2+) influx through nAChRs (PubMed:27344019). In vitro, specifically inhibits alpha-3:beta-4 and alpha-7 nAChR currents in an allosteric manner (PubMed:34631692). Acts as a positive regulator of Wnt/beta-catenin signaling (By similarity)

The "LYPD6 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LYPD6 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets